Stockwinners Market Radar for August 16, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:00 EDT Hill International to be bought by Global Infrastructure Solutions for $2.85/shr - Hill International "announced it has entered into a definitive merger agreement with Global Infrastructure Solutions, the largest privately owned construction manager in the commercial building, industrial and healthcare markets, and a leading project/construction manager in the environmental and public infrastructure sectors. Under the terms of the merger agreement, GISI will commence an all-cash tender offer to acquire 100% of the issued and outstanding shares of Hill for $2.85 in cash per share, representing a premium of 62.8% to Hill's closing share price on August 16, 2022. Following the successful completion of the tender offer, GISI will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price, making Hill a privately held company under the GISI banner. The transaction values Hill International share capital at $173M."

20:09 EDT Cathie Wood's ARK Investment bought 299K shares of SomaLogic today

18:36 EDT User reports indicate problems at Etsy, Downdetector says - Reference Link

18:28 EDT Fast Acquisition; Special Opportunities Fund reach deal on share distribution - Special Opportunities Fund (SPE) "announced that the parties to litigation over the dissolution of FAST Acquisition Corp. (FST) have reached an agreement to prevent the distribution of the Company's net assets to Class B shares until the Court rules on whether they must be equitably distributed to all stockholders. Under the agreement, the Class A shares will be redeemed promptly after August 25, 2022 and the winding up and dissolution of the Company will proceed. However, unless prior notice is given to SPE, the Company is limited to paying only the following approximate amounts: (a) $4.5 million in taxes; (b) $1 million to reimburse a working capital loan; (c) $3 million in professional fees previously incurred; (d) $1 million for defense costs in connection with the litigation; and (e) expenses incurred to enforce the Termination and Settlement Agreement with Fertitta Entertainment, Inc., if necessary."

17:43 EDT Rollins Chairman Gary Rollins sells $21.3M in shares - Rollins Chairman Gary Rollins disclosed in a filing that he had sold 577,764 shares of company stock at $36.85 per share between August 12 and August 15 for a total transaction amount of $21,292,626.

17:27 EDT Southern Company recommends stockholders against mini-tender offer - Southern Company announced that it has been notified of an unsolicited "mini-tender" offer dated August 12 made by TRC Capital Investment Corporation, a private Canadian investment company, to purchase up to 2,000,000 shares of Southern Company's common stock. TRC's unsolicited "mini-tender" offer price of $74.88 per share is approximately 4.14% below the $78.12 per share closing price of Southern Company's common stock on August 12 the last trading day prior to the date of the offer. Southern Company is in no way affiliated with TRC, the offer, or the offer documentation. Southern Company recommends against stockholders tendering shares in response to this unsolicited offer, for the reasons described herein. TRC has made many similar unsolicited mini-tender offers for the shares of other public companies. Mini-tender offers seek to acquire less than 5% of a company's shares outstanding. Consequently, they can avoid many disclosure and procedural requirements of SEC rules that apply to offers for more than 5% of a company's shares outstanding. The SEC has cautioned investors about mini-tender offers, stating that mini-tender offers "have been increasingly used to catch investors off guard," and that investors "may end up selling their securities at below-market prices."

17:15 EDT Blink Charging applauds signing of Inflation Reduction Act of 2022 - Blink Charging applauded President Biden for signing the Inflation Reduction Act of 2022. The Inflation Reduction Act lifts the 200,000-unit-per-manufacturer cap on EV sales while keeping the $7,500 consumer income tax credit for purchasing a new EV. There is now an additional new $4,000 credit for purchasing a used EV. The law extends the tax credit for alternative fuel refueling property to property placed in service before December 31, 2032 and removes the per location limitation. In addition, the law provides $3B for the U.S. Postal Service to purchase zero-emission vehicles.

17:00 EDT Rumble launches free livestreaming for creators - Video-sharing platform Rumble announced that the company has launched free unlimited livestreaming for content creators with over one hundred subscribers. Unlimited livestreaming, which was previously only available via a paid monthly subscription, will now be available to all content creators with over one hundred subscribers at no cost. "At Rumble, we are excited about the future of livestreaming. Introducing free unlimited livestreaming represents a key step forward to unlocking the potential of our creator community and enhancing the livestream experience," said CEO Chris Pavlovski. "We look forward to continuing to bolster our livestreaming toolkit for our creators and supporting their creative independence." Rumble announced in December 2021 the execution of a definitive business combination agreement with CF Acquisition Corp. VI, a special purpose acquisition company.

16:58 EDT Quanterix CFO buys $309K in common stock - In a regulatory filing, Quanterix disclosed that its CFO Michael Doyle bought 30K shares of common stock on August 12th in a total transaction size of $309K.

16:49 EDT Eagle Bancorp says SEC, FRB grant final approval for settlement - Eagle Bancorp, Inc., holding company for EagleBank, announced the Securities and Exchange Commission and Federal Reserve Board have granted final approval for the settlement of charges relating to the company's identification, classification and disclosure of related party transactions; and the relationship of the company and certain of its former officers and directors with a local public officials. "We are pleased that the SEC and FRB have approved the settlements and we can now put these legacy matters behind us and continue our focus on running one of the most profitable community banks in the Washington, DC region," said Susan Riel, Chief Executive Officer at EagleBank. "I would like to thank the entire EagleBank team for their unwavering support and dedication in continuing our mission of being a leading community bank in the region by doing what we do best, supporting our clients, our community, our employees, and our shareholders and putting Relationships First in all that we do."

16:47 EDT Blue Bird 'applauds' signing of Inflation Reduction Act - Blue Bird said it applauds the Inflation Reduction Act of 2022 signed into law Tuesday by U.S. President Joe Biden. The Inflation Reduction Act authorizes a $369B investment in energy security and combating climate change - the largest investment of its kind in U.S. history. The legislative action is projected to reduce harmful carbon emissions by roughly 40% by 2030, Blue Bird said. "The Inflation Reduction Act demonstrates America's leadership in advancing clean transportation solutions to help fight climate change," said Matthew Stevenson, president and CEO, Blue Bird Corporation. "As the leader in electric and low-emission school buses, Blue Bird welcomes all initiatives that foster a clean energy future and advance student and community health."

16:39 EDT Tesla announces first Model Y deliveries in Australia, New Zealand - Tesla announced on Twitter the first Model Y deliveries in Australia and New Zealand. Reference Link

16:34 EDT Eagle Bancorp charged by SEC with failing to disclose related party loans - The Securities and Exchange Commission charged Eagle Bancorp, Inc., based in Bethesda, Maryland, and its former CEO and Chairman of the Board, Ronald D. Paul, with negligently making false and misleading statements about related party loans extended by the bank to Paul's family trusts. Eagle and Paul have agreed to settle the SEC's charges. The SEC's order against Eagle finds that, from March 2015 through April 2018, Eagle failed to include loans to Paul's family trusts totaling at times nearly $90M in the related party loan balances included in its annual reports and proxy statements. The SEC's order also finds that, following a December 2017 short seller's report asserting Eagle had made significant undisclosed loans to Paul's family trusts, Eagle and Paul falsely stated in press releases, news articles, and meetings with investors that the trust loans were not related party loans and that Eagle was in compliance with all related party loan requirements. The SEC's order finds that Eagle violated the negligence-based anti-fraud, proxy, reporting, books and records, and internal accounting controls provisions of the federal securities laws. Without admitting or denying the SEC's findings, Eagle agreed to cease and desist from future violations and to pay disgorgement of $2.6M, prejudgment interest of $750,493, and a civil penalty of $10M. In a parallel action, the Federal Reserve Board announced settled enforcement actions against EagleBank and Paul.

16:32 EDT Corporacion America Airports reports July passenger traffic up 99.3% - Corporacion America Airports reported a 99.3% YoY increase in passenger traffic in July 2022, reaching 78.9% of pre-pandemic levels of July 2019.

16:31 EDT Avaya receives NYSE notice regarding late 10-Q fifling - Avaya Holdings Corp. reported that it had received a notice from the New York Stock Exchange notifying the company that, because the company did not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, it is not in compliance with Section 802.01E of the NYSE Listed Company Manual, which requires that NYSE-listed companies timely file all periodic reports with the Securities and Exchange Commission. The company had previously disclosed that it would not be able to timely file the Form 10-Q due to the circumstances described in the Form 12b-25 filed with the SEC on August 9, 2022. The Notice is a routine notification to NYSE-listed companies who are untimely in filing their periodic reports, and has no immediate effect on the listing of the company's common stock on the NYSE. The Notice informed the company that, under the NYSE's rules, the company has six months from the date of the Notice, until February 15, 2023, to file its Form 10-Q and regain compliance with the NYSE listing standards. If the company fails to file the Form 10-Q by the six-month deadline, the NYSE may, in its sole discretion, grant an extension of up to six additional months for the company to regain compliance, depending on the specific circumstances. Under NYSE rules, the NYSE may also commence delisting proceedings at any time if it deems that the circumstances warrant such proceedings.

16:25 EDT Plains All American pursuing Fort Saskatchewan facility expansion - Plains Midstream Canada, a subsidiary of Plains All American announced it is exploring the expansion of its Fort Saskatchewan facility with strategic partners. The expansion would leverage existing infrastructure and add 50,000 barrels per day of C3+ fractionation capacity, while maintaining the flexibility to deliver a propane/butane mix to Plains' fractionation facility in Sarnia, Ont. "With our integrated asset base, we are well positioned to provide competitive and capital-efficient solutions that align with customer needs and our long-term strategy," says Michelle Podavin, Senior Vice President, NGL Commercial Assets, Plains Midstream Canada. "Plains is excited to develop this expansion project to meet the growing needs of our customers for reliable, responsibly produced energy across North America."

16:16 EDT LHC Group to purchase provider Three Rivers Home Health - LHC Group announced an agreement to purchase Three Rivers Home Health, a provider headquartered in Eastman, Ga. The acquisition includes nine total locations - expanding LHC Group's service footprint in 36 counties in the Certificate of Need state of Georgia. The acquisition is expected to close in the Q4, subject to customary closing conditions. LHC Group expects annualized revenue from this purchase of approximately $12M and that it will not materially affect its 2022 diluted EPS. Three Rivers Home Health will continue operating under its current name and from its present locations. There will be no interruption in the care provided to patients.

16:16 EDT Evans Bancorp raises semi-annual dividend to 64c per share from 62c - Evans Bancorp announced that its Board of Directors declared a cash dividend of 64c per share on its outstanding common stock. This semi-annual dividend represents a 2c increase from the previous semi-annual dividend paid in April 2022. The dividend is payable on October 4, 2022 to shareholders of record as of September 13, 2022. The company has approximately 5.5M shares outstanding.

16:11 EDT Intercept announces settlement agreement with Dr. Reddy's over Ocaliva - In a regulatory filing, Intercept Pharmaceuticals (ICPT) and its subsidiary Intercept Pharma Europe Limited entered into a settlement agreement with Dr. Reddy's Laboratories (RDY) and Dr. Reddy's Laboratories, Ltd. resolving the previously disclosed patent litigation concerning the submission by Dr. Reddy's of an Abbreviated New Drug Application seeking approval to market a generic version of Ocaliva 5 mg and 10 mg tablets prior to expiration of the company's U.S. Patent Nos. RE48,286; 9,238,673; 10,047,117; 10,052,337; 10,174,073; 10,751,349; and 10,758,549. Under the terms of the agreement, Intercept granted Dr. Reddy's a non-exclusive, non-sublicensable, non-transferable, royalty-free license to commercialize its generic version of Ocaliva in the United States commencing on October 26, 2035, or earlier under certain circumstances. The parties will file the settlement agreement with the Federal Trade Commission and the Department of Justice pursuant to applicable law and will terminate their pending litigation pursuant to a consent judgment that is subject to court approval. Similar patent litigation previously disclosed by the company against five other ANDA filers seeking approval to market generic Ocaliva remains pending.

16:08 EDT Kronos Bio and Invivoscribe to develop CDx to use with entospletinib - Kronos Bio and Invivoscribe, a global provider of diagnostic kits and services for oncology, announced their agreement to develop a companion diagnostic, or CDx, for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia, or AML.The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.

16:05 EDT Ambrx Biopharma names Kate Hermans interim CEO - Ambrx Biopharma announced the appointment of Kate Hermans as interim Chief Executive Officer, replacing Feng Tian, Ph.D., effective immediately. Dr. Tian has agreed to remain available to the company in an advisory capacity. Ambrx's Board of Directors has commenced a search for a permanent CEO. Concurrently, Katrin Rupalla, Ph.D., has been appointed Chair of Ambrx's Board, replacing Dr. Tian. Along with these personnel changes, Ambrx plans to conduct a strategic review of its development pipeline to maximize our commercial opportunities and further extend the cash runway. Ambrx remains confident in the clinical data of its drug candidates, in its platform technology, and in the ongoing promise of precision biologics. In the near-term, the company will also prioritize strengthening its third-party partnerships, including with its China partner NovoCodex. Concurrent to Ms. Hermans appointment, Katrin Rupalla, Ph.D., was appointed Chair of the Board of Directors, replacing Dr. Tian. Dr. Rupalla has served on the Board since April 2021 and has more than 25 years of experience in the pharmaceutical industry at a global scale.

16:01 EDT OFS Credit estimates NAV per share of $10.56-$10.66 as of July 31, 2022 - OFS Credit Company announced the following net asset value estimate as of July 31, 2022. "Management's unaudited estimate of the range of our NAV per share of our common stock as of July 31, 2022 is between $10.56 and $10.66," the company said. "This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share as of July 31, 2022, which will be reported in our monthly report on Form N-PORT, may differ from this estimate. Our financial condition, including the fair value of our portfolio investments, and results of operations may be materially impacted after July 31, 2022 by circumstances and events that are not yet known. To the extent our portfolio investments are adversely impacted by the COVID-19 pandemic, changes in base interest and inflation rates, the ongoing conflict between Russia and Ukraine, or by other factors, we may experience a material adverse impact on our future net investment income, the underlying value of our investments, our financial condition and the financial condition of our portfolio investments."

15:09 EDT Digital World Acquisition files notice of late filing of 10-Q - Digital World Acquisition reports that it is unable to file its Form 10-Q for the quarterly period ended June 30, 2022 within the prescribed time period without unreasonable effort or expense because additional time is needed to prepare the financial statements for the quarterly period ended June 30, 2022. The company anticipates that it will file its Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended, it stated. For the three months ended June 30, 2022 and 2021, the Registrant had net loss of approximately $4.7 million and $740, respectively. For the six months ended June 30, 2022 and 2021, the company had net loss of approximately $6.5M and $1,225, respectively, though those amounts are still under review by the company's independent registered public accounting firm and accounting staff and may differ once reported in the Form 10-Q to be filed, the notice stated.

14:02 EDT GSK says plaintiff in first U.S. Zantac trial to file for voluntary dismissal - GSK plc issued the following statement regarding U.S. Zantac litigation: "The Plaintiff's counsel for Joseph Bayer, whose case was scheduled to be the first Zantac trial, informed the court and the parties yesterday that he will file a Notice of Voluntary Dismissal. GSK did not settle Mr. Bayer's claim and has not paid anything in exchange for the voluntary dismissal. GSK welcomes this outcome and believes the dismissal of Mr. Bayer's case is the correct result. The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk associated with the use of ranitidine. GSK will continue to vigorously defend itself against all claims alleging otherwise." GSK noted that the company has been named as a defendant in approximately 3,000 filed personal injury cases in federal and state court. Class actions alleging economic injury and a third-party payer class action also has been filed in federal court. "The MDL Court is scheduled to hold a hearing on defendants' motion to exclude plaintiffs' causation experts under Daubert on 20-21 September 2022. Among the state court cases naming GSK, a trial in California is currently scheduled to begin 13 February 2023 and a trial is currently scheduled to begin in Madison County, Illinois in February 2023. Given the early stage of this litigation, it is not possible to quantify or reliably estimate what liability (if any) GSK or any other parties may have in this litigation. Further announcements will be made as there are significant developments in the litigation," the company stated.

13:48 EDT Polestar electric roadster concept planned to enter production as Polestar 6 - Polestar confirms plans to put the Polestar electric roadster concept into production. The production car is expected to launch in 2026 as the Polestar 6 electric performance roadster. Interested customers in all active Polestar markets are able to reserve a build slot online from 16 August 2022. Revealed in Los Angeles in March as the Polestar O2, the electric roadster concept builds on the design, technology and sustainability ambitions laid out by the Polestar Precept and showcases the brand's vision for future sports cars, the company said. The hard-top convertible will be built on Polestar's bespoke bonded aluminium platform. Developed in-house, it will feature the high-performance, 800-Volt electric architecture already confirmed for Polestar 5. This includes output of up to 650 kW and 900 Nm from a dual motor powertrain, a targeted 0-100 km/h sprint time of 3,2 seconds and a top speed of 250 km/h. Reference Link

13:04 EDT Aerojet Rocketdyne opens SCEPS manufacturing facility - Aerojet Rocketdyne has officially opened its Center of Excellence for Undersea Propulsion to support the U.S. Navy's next generation torpedoes. the facility will be used to produce the undersea propulsion known as Stored Chemical Energy Propulsion System and the entire torpedo afterbody. Aerojet Rocketdyne independently funded the facility modernization, located at the company's Coleman Aerospace subsidiary. The company will manufacture SCEPS boilers, produce tail cones and fully assemble the torpedo afterbody. The new manufacturing facility will be used to support production for existing Aerojet Rocketdyne contracts, including the MK 54 MOD 2 Advanced Lightweight Torpedo prototype.

12:06 EDT Carnival says booking activity for Monday, Aug. 15 nearly double 2019 level - After announcing last Friday that it was revising pre-cruise vaccination and testing requirements that will allow more guests to sail, Carnival Cruise Line announced that its booking activity for Monday, Aug. 15 was nearly double the level for the equivalent day in 2019. "We have previously disclosed strong occupancy projections for the summer, and our bookings through the end of 2022 have also been very solid. With the further alignment of protocols to other vacation choices, our guests are booking the remaining 2022 inventory, and getting a head start planning for 2023. Mid-August is typically not a busy month for cruise bookings, but it's clear that pent-up demand for Carnival has not been satisfied and guests are responding very favorably to our updated protocols," said Christine Duffy, president of Carnival Cruise Line.

12:00 EDT Sea Limited falls -15.1% - Sea Limited is down -15.1%, or -$13.56 to $76.41.

12:00 EDT Sunlight Financial falls -29.4% - Sunlight Financial is down -29.4%, or -$1.31 to $3.14.

12:00 EDT Blend Labs rises 23.0% - Blend Labs is up 23.0%, or 64c to $3.40.

11:58 EDT Nasdaq says Vinco Ventures trading to resume today at 12:30 p.m. ET - The Nasdaq Stock Market announced that trading will resume in Vinco Ventures (BBIG) at 12:30 p.m. Eastern Time on August 16. Trading in the company's stock was halted on August 4 at 1:44:39 p.m. Eastern Time.

11:32 EDT Bed Bath & Beyond trading resumes

11:27 EDT Bed Bath & Beyond trading halted, volatility trading pause

11:07 EDT VTEX, Signifyd enter strategic alliance for Latin America - Signifyd and VTEX announced a strategic alliance to promote, strengthen and protect retailers and online businesses in Latin America. Through its connected and complete digital commerce platform, and a team of specialists in digital commerce, the multinational of Brazilian origin is helping companies achieve a faster time to market, reach their customers through any channel, personalize experiences and discover new areas of growth. VTEX customers now have access to Signifyd's Commerce Protection Platform module through the VTEX App Store. This means that they will be able to install a plug-in within the VTEX ecosystem and thus optimize their transactions, protect their profits and prevent abuse and fraud attempts.

11:06 EDT Gilead says Veklury shows continued in vitro activity against Omicron variants - Gilead has conducted in vitro analyses of Veklury activity against Omicron subvariants BA.2.12.1, BA.4 and BA.5, which are currently the most common circulating variants, the company announced. "Results continued to confirm that Veklury retains antiviral activity against all Omicron subvariants analyzed to date," the company stated. Tomas Cihlar, Senior Vice President of Virology Research, Gilead Sciences, said: "Gilead continuously evaluates the activity of Veklury against viral variants of SARS-CoV-2. These new data build on previous evidence of the durable antiviral activity of Veklury across known variants that have emerged throughout the pandemic. There remains a critical need for Veklury, especially for higher risk patients as the pandemic continues to evolve, and these data help provide continued confidence in this treatment." Reference Link

11:04 EDT BAE Systems to deliver advanced ballistic missile seekers - BAE Systems (BAESY) has received a contract from Lockheed Martin (LMT) to design and manufacture next-generation infrared seeker technology for the Terminal High Altitude Area Defense interceptor missile. The THAAD seeker provides critical sensing and guidance capabilities that help protect the U.S. and global allies from ballistic missiles.

10:54 EDT Jack in the Box offering multi-unit incentive program for franchisees - As part of its aggressive franchise growth strategy, Jack in the Box announced an incentive program with multi-unit franchisees that offers financial benefits to those who enter into a minimum three-unit development agreement. "We have a clear vision for growth, and offering this industry-leading incentive to new and existing franchisees moves Jack in the Box to the top of the list for QSR opportunities," said Tim Linderman, Chief Development Officer of Jack in the Box. "The more we're able to support our multi-unit operators, the better the Jack in the Box franchise system becomes overall." The financial incentives of the program focus on discounted royalty fees for new franchisees who maintain development compliance and sign at least three franchise agreements by March 2023. For the first five years of the unit being open, Jack in the Box will offer discounted royalty fees for new franchisees, starting at 1% the first year, 2% the second, 3% the third year, 4% the fourth year and then 5% for the remainder of the agreement starting in the fifth year.

10:46 EDT Knightscope announces deployment of K5 ASR at Texas manufacturer - Knightscope announced that a Houston manufacturer of premium quality lubricants and associated products for the automotive, industrial and drilling markets has successfully deployed its Knightscope K5 Autonomous Security Robot to help protect this industrial plant and storage facility in the northeast corner of the city.

10:44 EDT BankProv announces strategic integration with Republic - BankProv announced that it will team up with Republic. The Republic ecosystem has deployed over $1.5 billion in capital, supports over 600 companies, and includes over two million community members across 150 countries. Through the collaboration, Republic will offer escrow accounts to companies looking to raise capital from investors on their platform. The Republic platform provides investors with access to vetted investment opportunities in startups, real estate, video games, crypto, and other verticals as well as syndicated funds and alternative investment opportunities. Republic was created to support fundraising efforts, expand equity investing to the masses and empower individuals by providing financial education.

10:33 EDT VOXX Automotive, ESS sign deal for H.E.L.P. availability - VOXX Automotive announced it is partnering with Emergency Safety Solutions to make H.E.L.P available to virtually every passenger and commercial vehicle on the road. Under the agreement, VOXX Automotive will design and manufacture OEM accessory and aftermarket kits featuring these products for sale across all VOXX Automotive and ESS sales channels. The scope of the agreement also includes H.E.L.P. DeliverSAFE, a specialized version of H.E.L.P. tailored to the needs of heavy-duty, long-haul, and commercial delivery vehicles.

10:20 EDT Sanuwave Health appoints Toni Rinow as CFO - SANUWAVE Health announced the appointment of Dr. Toni Rinow, MBA as CFO. Toni led healthcare organizations as General Manager at global nuclear medicine leader Jubilant Draximage Inc and as Chief Operating Officer at Isologic Innovative Radiopharmaceuticals.

10:00 EDT Bloom Energy falls -10.0% - Bloom Energy is down -10.0%, or -$3.04 to $27.32.

10:00 EDT Sunlight Financial falls -22.9% - Sunlight Financial is down -22.9%, or -$1.02 to $3.43.

10:00 EDT Blend Labs rises 26.4% - Blend Labs is up 26.4%, or 73c to $3.49.

09:58 EDT Home Depot says comparable sales growth 7.1% in July - Expects comp sales stronger in 1H22 vs. 2H22. Says has not seen any decline in the business from the macro housing market. Says "could not feel better about the business." Seeing "very resilient, engaged customer." Says acceleration of business in July has carried over into August. Says feels "very good" about in-stock position. Says "better positioned than ever" to take market share in any environment. Says demand is strong with larger Pro customer. Says "super happy" with loyalty customers, enrollments strong. Says taking conservative approach to guidance.

09:50 EDT BioSig expects to see increase in enterprise adoption of PURE EP System - BioSig Technologies said, "it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP System in the coming months. Since BioSig's national commercial launch of its PURE EP System on July 1st, 2022, the Company's commercial pipeline has experienced a steady increase in advanced leads and technology adoption across several key regions and centers of excellence. Under the terms of its new leasing program, the Company recently signed a purchase agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center. In addition, the Company inked its first master services agreement with one of the largest U.S. healthcare systems. Among several key regions, BioSig's PURE EP System continues to gain interest in hospitals across the Midwest, including new evaluation agreements with the Cleveland Clinic, a leading Medical Center of Excellence, and an additional installation at a leading medical center in Springfield, IL."

09:47 EDT Sunlight Financial falls -10.1% - Sunlight Financial is down -10.1%, or -45c to $4.00.

09:47 EDT IonQ rises 15.1% - IonQ is up 15.1%, or 96c to $7.32.

09:47 EDT Ginkgo Bioworks rises 21.8% - Ginkgo Bioworks is up 21.8%, or 76c to $4.25.

09:40 EDT WeTrade Group Inc trading resumes

09:30 EDT Wildpack Beverage reports July throughput of 20.1M equivalent cans - Mitch Barnard, Chief Executive Officer commented "When we purchased Land & Sea, we saw the segment as a much-needed complement to our existing co-pack, fill and decorate business. Can and package brokering presents the least capital intensive, highest scalability segment of our complementary business and we are seeing sustainable demand. We continue to work towards optimal domestic can supply contracts, which will elevate that business even further and enhance our vertically integrated value proposition of co-pack, fill, decorate, broker and logistics as we importantly continue to meet and exceed customer needs." In July 2022, Wildpack achieved a record for equivalent standard 12-ounce can throughput of 20.1 million cans. This represented a 7.6% month-over-month increase. Wildpack's throughput results, which include cans and can equivalents, are trending towards profitability and positive cashflow. In the month, can decorating, can filling, sleeve printing, and brokering operations all had throughputs above Wildpack's reported first quarter throughput. Can decorating achieved 3.9 million units, the second highest throughput in the Company's history. Can filling achieved 865 thousand units, in line with first quarter monthly averages. Printing operations achieved 2.8 million units produced, the second highest monthly throughput since the initiation of printing services in December 2021. Can brokering increased 18% MoM while the add-on business of packaging sales increased 4.7% MoM. Wildpack's total sales orders for the month of July were 115, with 16 new customer conversions. As reported in Wildpack's first quarter 2022 financials, plant utilization was 15.8%, while July increased 47% over these first quarter averages, to 23.3%, as part of the trend toward our medium-term operational goals. Production line yields have remained above 90% for the duration of the month despite the increase in utilization. Wildpack's brokering division secured its first multi-year contract to supply more than 50 million printed cans and can ends to a single customer on an annual basis.

09:29 EDT Lumentum: Will take ~24 months to return to prior LT model of 50%+ gross margins - Lumentum said on its Q4 earnings conference call that it will "probably" take around 24 months for the company to return to its prior long-term model of 50%+ gross margins and 30%+ operating margins.

09:29 EDT Osino Resources to acquire minority interests in Twin Hills Gold Project - Osino Resources announced that the Company has entered into two agreements to acquire the remaining minority interests in the mineral properties comprising the Twin Hills Gold Project. Osino signed an agreement with Somerschield Investments Close Corporation to acquire 3% of the shares in the capital of Osino Gold Exploration and Mining for an aggregate value of C$1,870,000 payable through the issuance of 1,700,000 common shares of the Company. Osino GEM is a 97% owned subsidiary of Osino and holds 3 Namibian exclusive prospecting licenses covering a total of 24,171 hectares, including an EPL which holds most of the Bulge and Twin Hills Central mineralization, forming part of Osino's overall Twin Hills gold mineral resource. Osino also signed an agreement with Ominda Mineral Resources Close Corporation, who is arm's length to Osino, to acquire 10% of the shares in the capital of Osino Namibia Minerals Exploration for an aggregate value of C$870,000 payable through the issuance of 1,000,000 common shares of the Company. ONME is a 90% owned subsidiary of Osino and holds 8 EPL's covering a total of 86,409 hectares, including an EPL which hosts the gold mineralization at the Clouds deposit, forming part of Osino's overall Twin Hills gold mineral resource. The Acquisitions will result in Osino owing 100% of ONME and 100% of Osino GEM. The common shares of the Company to be issued under the Ominda Agreement shall be subject to a restriction from resale for a period of 24 months from the date of closing. The common shares of the Company issued under the Somerschield Agreement will be subject to resale restrictions over a 24-month period from the date of closing wherein 20% will be subject to resale restrictions for 3 months from the date of closing, 20% for 6 months, and 10% for each 3-month period thereafter. Somerschield is owned and controlled by Lazarus Shigwedha, who is a director of the Company and therefore the Somerschield Transaction is a "related party transaction" pursuant to Multilateral Instrument 61-101-Protection of Minority Security Holders in Special Transactions. The Company is exempt from the requirements to obtain formal valuation and minority shareholder approval in connection with the Somerschield Transaction in reliance, respectively, on Section 5.5(b) of MI 61-101 as the Company is not listed on a "specified market" and on Section 5.7(1)(a) of MI 61-101 as the fair market value of the Somerschield Transaction is not more than 25% of the market capitalization of the Company. The Somerschield Agreement and the Somerschield Transaction contemplated by it were reviewed and approved by a resolution of all of the directors of the Company other than Mr. Shigwedha who declared his interest in the transaction and abstained. The Somerschield Transaction was negotiated independently with Mr. Shigwedha by management of the Company. As a consequence of the Somerschield Transaction, Mr. Shigwedha will acquire 1,700,000 common shares of the Company representing 1.24% of the issued and outstanding number of shares, which will increase his ownership of the Company to 1,752,877 common shares. Neither the Somerschield Transaction nor the Ominda Transaction would result in the creation of a new control person. To the Company's knowledge, there is no material information concerning the Company or its securities that has not been generally disclosed. In addition, Osino also signed an agreement with Richroad Investments Close Corporation and South Wing Investments Close Corporation, who are arm's length to Osino, to acquire 20% of the shares in Richwing Exploration for an aggregate value of C$137,931, payable through the issuance of 37,617 shares and a cash payment of C$96,552 to Richroad and Southwing. Richwing is 80% owned by Osino and holds an EPL which hosts gold mineralization and industrial minerals south of the Twin Hills project area. Upon closing of the transaction Osino will own 100% of Richwing. The common shares of the Company to be issued under the Richwing Agreements shall be subject to a restriction from resale for a period of 24 months from the date of closing. In addition, all common shares of the Company issued under the agreements for all three acquisitions shall be subject to a statutory four month hold from the date of issuance. No finders fees are payable in respect of any of the acquisitions. All three of the acquisitions are subject to approval of the TSX Venture Exchange.

09:26 EDT Natural Gas Services announces rescheduled Q2 earnings call - Natural Gas Services Group announced it has rescheduled it second quarter earnings conference call. The call will now be held on Tuesday, August 16, 2022 at 10:00am ET. "Due to a technical glitch by our conferencing services provider, the connection to our scheduled earnings call was compromised," said John Chisholm, the Interim President and Chief Executive Officer. "We apologize for the inconvenience and look forward to talking to you at that time."

09:21 EDT Smart for Life announces the 'Director's Forum' - Smart for Life announced the release of the "Director's Forum," a newly inaugurated video series featuring the independent members of Smart for Life's board of directors, their backgrounds and their individual views on the Company and its growth strategy. This installment highlights Ronald S. Altbach, a prominent capital markets executive and independent director since October 2020.

09:19 EDT RocketFuel Blockchain teams up with Genius X for token offering - RocketFuel Blockchain announced that it has teamed up with Genius X, an accelerator and launchpad platform built for boosting start-ups and projects on Cardano, to help with the design and launch of a token offering linked to RocketFuel's upcoming loyalty program, and to assist in investor outreach. The tokens will allow RocketFuel customers to redeem, unlock and purchase additional services and products like airline upgrades, hotel bookings, concert shows, sports events, etc. Customers can also earn tokens when they make purchases on RocketFuel's payment ecosystem.

09:15 EDT AvePoint achieves ISO 27001:2013, 27017:2015, CSA Star Level 2 certifications - AvePoint announced re-certification and demonstration of conformance to the International Organizations for Standardization's information security management system audit using the 27001:2013, and 27017:2015 frameworks as well as certification against Cloud Security Alliance Security, Trust, Assurance and Risk Level 2. AvePoint's achievement of three external audits reflects their prioritization of security and privacy for both the organization and its customers with enhanced abilities to help them mitigate access risk, reduce security breaches, and strengthen audit and compliance posture.

09:12 EDT Home Depot says all U.S. regions delivered positive comps in Q2 - Says business is strong across all departments. Saw growth with Pro and DIY customers in Q2 with Pro outpacing DIY. Says continues to invest in capabilities to attract the Pro customer. Says big ticket transactions up 11.6% y/y. Says investments in digital capabilities "resonating" with customers. Comments taken from Q2 earnings conference call.

09:11 EDT EnWave signs Technology Evaluation Agreement with Canadian cannabis cultivator - EnWave announced that it has signed a Technology Evaluation Agreement with a leading Canadian cannabis company, to use a 10kW Radiant Energy Vacuum dehydration machine at their main cultivation and production facility in Canada. The 10kW machine will be utilized for the drying of cannabis flower and derivatives for the adult-use Canadian market. The Cannabis Cultivator will trial REV technology over a six-month period to thoroughly evaluate all post-harvest improvements offered by EnWave's patented technology.

09:10 EDT Sorrento Therapeutics announces expanding coverage for ZTlido 1.8% - Scilex Holding, a subsidiary of Sorrento Therapeutics (SRNE), announced that, effective September 1, 2022, ZTlido 1.8% will be added to one of the largest national PBMs and a national health plan - thereby expanding coverage to 30 million lives and Scilex will continue to work with them to access an additional 20 million lives. ZTlido is indicated for relief of pain associated with post-herpetic neuralgia, also referred to as post-shingles pain. "Scilex commercial team continues to demonstrate success in expanding access and has prioritized and targeted select payor accounts to further improve the access for ZTlido," said Jaisim Shah, Chief Executive Officer of Scilex Holding Company. Scilex Holding Company and Vickers Vantage Corp. I (VCKA), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI Pte Ltd, have entered into a definitive business combination agreement on March 17, 2022.

09:08 EDT WWE announces record first-day ticket sales for WrestleMania 39 - WWE announced a record for first-day ticket sales for WrestleMania 39 taking place at SoFi Stadium in Los Angeles. Over 90,000 tickets were sold within the first 24 hours - more than any event in WWE history and a 42% increase over first-day sales for WrestleMania 38 at AT&T Stadium in Dallas.

09:07 EDT M&T Bank appoints Ishet Dhar as Chief Digital Officer - M&T Bank announced the appointment of Ishet Dhar in the role of Chief Digital Officer. Dhar has over two decades of global experience, most recently serving as senior vice president, digital consumer delivery at Bank of America. In this enterprise-wide role, Dhar will lead the strategy, integration and transformation of M&T's digital platforms, providing each customer a seamless and personalized digital experience that spans and supports their full relationship across the bank. He will report to Head of Consumer / Business Banking and Marketing Christopher Kay and serve as a key member of the company's leadership. Dhar received a MBA from Rice University and currently resides in Newtown Square, Pa. He will be based in M&T's regional headquarters in Wilmington, Del.

09:06 EDT iBio provides update on development of next-gen COVID-19 vaccine candidate - iBio provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. The Company recently completed its first manufacturing run of its proprietary nucleocapsid antigen under cGMP conditions using its FastPharming System. IBIO-202 uses a portion of the nucleocapsid protein, which is more highly conserved. The recently produced N antigen is currently undergoing release testing and, if it clears, is intended for use in IBIO-202 clinical studies. "This is another important step in our mission to develop a 'last dose', not a 'next dose' of a COVID-19 vaccine," said Tom Isett, Chairman & CEO of iBio. "We believe there is a substantial unmet need for a vaccine that protects against existing - and potentially new - variants and for longer periods of time. While currently available spike protein-based COVID-19 vaccines have undoubtedly prevented severe disease and deaths for millions of people, hospitalizations and deaths have nevertheless again been on the rise recently in the U.S.3 This is primarily attributable to mutations specific to the virus' spike protein, like those associated with the BA.5 variant, that result in existing vaccines providing less protection or shorter periods of immunity."

09:05 EDT Digital Ally's TicketSmarter announces partnerships - Digital Ally announces its ticket marketplace subsidiary, TicketSmarter, has entered into several notable relationships with major motorsports venues in Texas and Illinois. Partnerships include: Presenting Sponsor of the Enjoy Illinois 300 NASCAR Cup Series race: As the official ticket resale partner of World Wide Technology Raceway and presenting sponsor of the event, TicketSmarter is featured with the race title sponsor, the Illinois Office of Tourism, on the Enjoy Illinois 300 race logo and featured prominently throughout the WWTR venue. Primary Ticketing Partner for the Texas Motorplex: As the primary ticketing partner for all events hosted by the Dallas-area drag racing facility, TicketSmarter will also receive premium signage on the suite tower, premium branding during the Stampede of Speed Music Festival, and various other marketing benefits. Primary Ticketing Partner for the Houston Raceway Park: TicketSmarter is the primary ticketing partner for all events ticketed by the Houston Raceway Park, located in Baytown, TX. TicketSmarter will also receive premium signage on the suite tower and premium walkover bridge signage.

09:04 EDT Artelo Biosciences reports pre-clinical results on FABP inhibitor platform - Artelo Biosciences announced publication of pre-clinical results indicating a novel fatty acid binding protein 5 inhibitor from the Company's FABP inhibitor platform reduces anxiety behaviors in an area of the brain known to be important in anxiety and that modulation of the FABP5 system may serve as a promising target for the development of novel anxiolytics. "What was particularly interesting was that we have demonstrated that the CB2 receptor, which is often thought of as the peripheral cannabinoid receptor, is involved in the control of both fear and anxiety and, importantly, is capable of being modulated by FABP5 inhibition for the first time," said Gregory Gorgas. President and Chief Executive Officer of Artelo Biosciences. "This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder."

09:02 EDT Saratoga Investment announces distribution of proxy materials for 2022 meeting - Saratoga Investment announced that the Company commenced distribution of the proxy materials to the Company's stockholders for the 2022 Annual Meeting of Stockholders to be held on September 29, 2022.

08:53 EDT Connexa Sports appoints Kirk Taylor to board of directors - Connexa Sports (CNXA) announced the appointment of Kirk Taylor as an independent director to its Board of Directors. Mr. Taylor, joining Rohit Krishnan and Gabriel Goldman as recent independent appointments to the new Connexa Sports Board. Mr. Taylor has been serving on the Board of Directors since June 15th. He serves as the CFO of American Resources Corporation (AREC) and President and CFO of American Acquisition Opportunity (AMAO).

08:45 EDT Vicinity Motor enters distribution agreement with TOK Group - Vicinity Motor announced that it has signed a distribution agreement with the TOK Group to offer the Company's VMC 1200 Class 3 electric trucks, including an initial commitment for 10 vehicles. Under the new agreement, TOK will distribute Vicinity's VMC 1200 Class 3 Electric Truck's throughout the York Region of the Greater Toronto Area. The VMC 1200 adds to TOK's portfolio expertise in electric vehicle sales. The agreement includes an initial commitment for 10 VMC 1200 vehicles.

08:44 EDT Intrusion enters agreement with OneSmartLaboratory - Intrusion announced an agreement with OneSmartLaboratory to protect the Intelligent Laboratory Automation initiative for all OneSmartLaboratory client operations and connectivity. Intrusion Shield will be utilized through this partnership to protect the link and transit connections of medical laboratories by identifying and blocking internal and external threats.

08:41 EDT Sellas Life Sciences elects Kalin to board of directors - SELLAS Life Sciences (SLS) announced the election of Katherine Kalin to its Board of Directors. Kalin's healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health. She currently serves as a non-executive director on the boards of Genfit (GNFT), a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory, an independent investment and strategic advisory firm, where she sits on the Audit and Finance Committees, and FemHealth Ventures, a venture capital firm that seeks to invest in women's health.

08:40 EDT Vicinity Motor in distribution pact with TOK Group for VMC 1200 electric truck - Vicinity Motor announced that it has signed a distribution agreement with the TOK Group, a Canadian transportation solutions provider, to offer the Company's VMC 1200 Class 3 electric trucks, including an initial commitment for 10 vehicles.The TOK Group of Companies has been providing comprehensive, quality services to public and private organizations in the transit, urban mobility and charter tour industries for nearly 50 years. Serving the bus, truck and industrial equipment industries across Canada and internationally, the TOK Group provides professional services, smart technologies and turnkey transit operation and maintenance solutions that are integrated, scalable, flexible and cost-effective.Under the new agreement, TOK will distribute Vicinity's VMC 1200 Class 3 Electric Truck's throughout the York Region of the Greater Toronto Area. The VMC 1200 adds to TOK's portfolio expertise in electric vehicle sales. The agreement includes an initial commitment for 10 VMC 1200 vehicles. "We continue to partner with larger, sustainability-minded North American dealers looking toward the future of electrification for their client's commercial fleets," said William Trainer, Founder and CEO of Vicinity Motor Corp. "TOK has 50 years of experience providing comprehensive, quality services to public and private organizations in the urban mobility, transit and charter tour industries.

08:38 EDT Eaton Partners acts as placement agent for HitecVision New Energy Fund - Eaton Partners is pleased to have acted as placement agent for the HitecVision New Energy Fund. The oversubscribed fund reached its hard cap of EUR 875 million, exceeding its EUR 500 million target.

08:37 EDT Intrusion announces agreement with OneSmartLaboratory - Intrusion announced an agreement with OneSmartLaboratory to protect the Intelligent Laboratory Automation initiative for all OneSmartLaboratory client operations and connectivity. Intrusion Shield will be utilized through this partnership to protect the link and transit connections of medical laboratories by identifying and blocking internal and external threats. Intrusion Shield allows OneSmartLaboratory ILA clients to utilize the internet without the worry of being compromised and enables them to connect to other reference labs, medical offices, hospitals, private data centers, and internet cloud providers securely from the Global Healthcare Array. Shield is highly adaptive, exceeds HIPAA regulations for Electronic Protected Health Information, and uses next-generation proprietary technology specifically designed to protect medical labs."We've seen an increase in the targeting of medical labs with ransomware. This exposes organizations to extensive threats due to the importance of medical information in determining the proper treatment for patients and the vitality of medical laboratory infrastructure to the overall healthcare system," said Tony Scott, Chief Executive Officer of Intrusion. "We are incredibly pleased with the results and believe integrating Intrusion Shield into the Global Healthcare Array will accelerate the security of medical labs."

08:36 EDT Evoke Pharma, EVERSANA expand patient access to GIMOTI - Evoke Pharma and EVERSANA, an independent provider of global commercial services to the life science industry, announced that Evoke, through its wide-scale commercialization partnership with EVERSANA, is launching a telehealth solution for patients. The new Direct-to-Patient Technology Solution will leverage EVERSANA's partnership with UpScriptHealth, a direct-to-consumer telehealth platform. The program allows patients who don't have regular access to care due to their remote location, lack of transportation, affordability, or work schedule to access care via a telehealth option. UpScriptHealth's telehealth solution provides access to care from a licensed board-certified healthcare provider when it is convenient, generally a same-day appointment with a healthcare provider. This may allow for more rapid consultation and potentially treatment initiation within just a few days, if medically appropriate.

08:35 EDT PFSweb selected by Wimbledon for UK fulfillment operations - PFS was selected by The All England Lawn Tennis Club to operate its global order fulfillment operations for the online Wimbledon Shop. Zach Thomann, COO and President of PFS, commented: "The Wimbledon brand has a rich history across the world, and we are excited to be a part of their legacy. Prioritizing the fulfillment and shipping process within the eCommerce channel is more important than ever, and a brand with their level of reputation brings an important responsibility for our team. We are excited for this challenge as we help Wimbledon grow their eCommerce channel and execute for their valued fans around the world."

08:34 EDT Walmart says Q3 back to school season off to solid start - Says plans to repurchase $10B-$11B of shares in FY23. Says Flipkart continues to meet expectations. Says when issuing guidance previously, did not expect food and fuel inflation at current levels. Says Q3 back to school season off to solid start. Says taking additional pricing actions in Q3.

08:33 EDT Nektar announces publication of preclinical data for NKTR-255 - Nektar Therapeutics announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natural killer, or NK, cell function and proliferation in multiple myeloma, or MM. "These findings published today in Blood Advances demonstrate the promising anti-tumor activity of IL-15 in engaging natural killer cell biology in indications with immunosuppressive tumor microenvironments as in multiple myeloma," said Nikhil C. Munshi, Professor of Medicine at Harvard Medical School, Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. The Dana-Farber team analyzed in vitro pharmacological properties of NKTR-255 in engaging the IL-15 pathway and stimulating NK cells against MM cells. The research also looked at the anti-tumor activity of combining NKTR-255 with the anti-CD38 antibody, daratumumab, in vitro and in vivo. "The published data demonstrate that NKTR-255 not only enhances antitumor responses of human NK cells against MM target cells, but also increases ex vivo expression of NK activating receptors and adhesion molecules. Furthermore, studies in a humanized MM mouse model show that NKTR-255 enhances in vitro antibody-dependent cellular cytotoxicity (ADCC) of NK cells and synergizes with daratumumab to reduce MM cell growth," said Mariateresa Fulciniti, the senior author on this manuscript at Dana-Farber. These preclinical findings support Nektar's robust clinical development program for NKTR-255 and further evaluation of the novel immunotherapeutic approach in MM, alone or in combination with monoclonal antibodies or potentially with other immunomodulatory drugs.

08:29 EDT American Airlines announces pact to purchase Boom Supersonic Overture aircraft - American Airlines and Boom Supersonic announced the airline's agreement to purchase up to 20 Overture aircraft, with an option for an additional 40. American has paid a non-refundable deposit on the initial 20 aircraft. Overture is expected to carry passengers at twice the speed of today's fastest commercial aircraft. In July, Boom revealed the final production design of Overture, which is slated to roll out in 2025 and carry its first passengers by 2029. "Looking to the future, supersonic travel will be an important part of our ability to deliver for our customers. We are excited about how Boom will shape the future of travel both for our company and our customers," said Derek Kerr, American's CFO. Reference Link

08:19 EDT Intellipharmaceutics signs exclusive license, supply agreement with Taro - Intellipharmaceutics International (IPCIF) announced that it has entered into a license and supply agreement with Taro Pharmaceuticals (TARO) by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.

08:18 EDT Aytu BioPharma issued first patent for AR101/Enzastaurin - Aytu BioPharma announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 for AR101/Enzastaurin. This patent, titled "Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition," covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFbeta genes, including Ehlers-Danlos Syndrome. This is the first issued patent supporting the portfolio and has an expiry date in August of 2038, assuming no patent term extensions.

08:16 EDT Nielsen, Amazon.com sign pact to measure Prime Video's NFL TNF telecasts - Nielsen (NLSN) and Amazon (AMZN) have signed a three-year agreement to measure Prime Video's exclusive NFL Thursday Night Football telecasts, a first-of-its-kind deal where a streaming service will be included in Nielsen's National TV measurement service. Starting with the 2022 NFL season, measurement will include full coverage of the TNF broadcast - pregame, in-game and postgame programming - on Prime Video and Twitch, as well as the over-the-air stations in teams' local markets each week, and out-of-home viewing. This will be the first time a streaming service will have one of its live programs measured as part of Nielsen's National TV measurement service, reinforcing Nielsen's ability to measure customers' changing viewing behaviors and how content owners are distributing programming. TNF will be measured and processed like all other NFL games, using Nielsen's panel, allowing for the same metrics to be reported across all other national networks, continued trending, and comparability. According to Nielsen's ratings, NFL games and shoulder programming such as pregame and postgame accounted for the top 27 live telecasts in 2021, and 47 of the top 50.

08:13 EDT QSAM Biosciences expects cash to support operations into 3Q22 - As of June 30, 2022, the Company had cash of approximately $0.43 million. The Company believes this is sufficient capital to support operations at the current pace into the third quarter of 2022. The Company expects to raise additional capital through equity or debt offerings in 2022 to support its clinical trials and other operating expenses.

08:10 EDT DZS expands relationship with Hamilton Telecommunications - DZS announced an expanded relationship with its long-time customer Hamilton Telecommunications, which is expanding its gigabit services capable footprint to newly acquired customers in 21 towns in Central Nebraska. This service buildout is complementary to a multi-year fiber construction process to deliver fiber-to-the-home for 100% of customers in the communities and rural areas in the traditional Hamilton Telecommunications footprint. The telecommunications pioneer has selected cutting-edge DZS broadband connectivity solutions, including the DZS Velocity Access Edge portfolio and DZS Helix Home Edge solutions, to deliver services up to one Gigabit of bandwidth today with the ability to be easily upgraded to multi-gigabit services in the future.

08:08 EDT NetSol Technologies signs agreement with finance bank of Swedish origin - NETSOL Technologies has signed an agreement with a consumer finance bank of Swedish origin. The multi-million-dollar contract is for the deployment of NETSOL's premier platform Ascent on the Cloud alongside NFS Digital. This is set out to be a multi-country implementation on a single instance using multi-tenancy options available in Ascent. The agreement scope for this signing covers the European Economic Area to be followed by the United Kingdom. "I am pleased to announce this multi-million-dollar signing with a new client that works with approximately 1500 partners in Northern Europe providing leasing, factoring and invoice to pay services covering a range of asset categories," said Asad Ghauri, President Asia Pacific and Group MD Europe, NETSOL Technologies, Inc. "The agreement scope initially covered the discovery phase and first country implementations with plans to move into implementations into other European countries. The countries currently included in this contract are Sweden, Norway, Denmark and Finland." "As the client has opted for Ascent Retail via the Cloud, they will benefit by a swift deployment process and flexible, volume-based subscription pricing," he added.

08:06 EDT Sono-Tek announces $1.1M order from clean energy sector - Sono-Tek announced that it has received an order valued at $1.1M from a customer in the clean energy sector. This is the largest order that Sono-Tek has received from the clean energy sector to date, one of the Company's target sectors for growth. The order is also among the largest in Sono-Tek's corporate history, a growing occurrence with Sono-Tek's increased focus on providing full system solutions. The order is expected to be shipped in the spring of 2023. Steve Harshbarger, President and COO of Sono-Tek, commented, "We're excited to receive this substantial order that validates the investments we've made to serve the clean energy sector. Significant investments from governments around the world are driving demand for clean energy products. Sono-Tek's application engineering expertise has been a vital part of our success in this sector. We have a large number of customers who are working with our highly experienced engineers and using our ultrasonic coating systems for R&D in carbon capture, hydrogen generation and fuel cell applications. Several of these companies have begun to make the transition to production volumes which can result in additional orders for Sono-Tek equipment, as is the case with this $1.1 million order, the largest we've received from the sector so far."

08:05 EDT Chembio Diagnostics evaluates monkeypox rapid POC test development - Chembio Diagnostics announced it is evaluating the potential to develop a monkeypox rapid point-of-care test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity. Currently, the FDA has cleared one test to detect monkeypox, offered through the U.S. Centers for Disease Control and Prevention as a lab developed test. The test utilizes a swab sample from a monkeypox lesion, creating the need for earlier detection to limit the spread of the disease and expedite treatment.

08:04 EDT Lightbridge receives notification of patent grant from the Korean Patent Office - Lightbridge announced that it has received a Notice of Patent Grant for a divisional patent from the Korean Patent Office based on the 2015 Patent Cooperation Treaty, PCT, patent application related to a CANDU fuel assembly design incorporating Lightbridge metallic fuel rods arranged into a mixed grid pattern that includes a first, rectangular grid pattern and a second, triangular grid pattern. Seth Grae, President and CEO of Lightbridge commented: "This latest patent in Korea further expands the broad global patent protection already surrounding our fuel design. Korea represents a significant potential market for Lightbridge metallic fuel with 25 operating pressurized water reactors and an additional 5 reactors either under construction or planned by 2025, according to the most current data compiled by the World Nuclear Association."

08:04 EDT Mersana Therapeutics announces initiation of Phase 1 trial of XMT-1660 - Mersana Therapeutics announced the initiation of patient dosing in the company's Phase 1 trial of XMT-1660, the company's Dolasynthen ADC targeting B7-H4. "The initiation of this Phase 1 trial represents an important milestone for Mersana as we continue to build our pipeline across three ADC platforms and seek to further demonstrate the potential of our Dolalock payload and Dolasynthen platform," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "Based on our promising preclinical data, we believe XMT-1660 has the potential to serve as a highly impactful cancer treatment. We are excited to begin investigating how it may benefit patients in a range of cancers with high unmet needs." XMT-1660 is a B7-H4-directed Dolasynthen antibody drug conjugate with a precise, target-optimized drug-to-antibody ratio and Mersana's clinically validated DolaLock microtubule inhibitor payload with controlled bystander effect.

08:03 EDT GreenBox appoints Byelick as Chief Financial Officer - GreenBox announced the appointment of J. Drew Byelick as the organization's Chief Financial Officer, CFO, effectively immediately. In conjunction with the appointment, Ben Chung, the Company's Chief Financial Officer, has resigned effective August 16, 2022. Most recently, Byelick was Chief Financial Officer at Aero Components where he improved the organization's practices and led the divestiture process.

08:02 EDT Otonomo Technologies selected by Geograma to advance road safety in Spain - Otonomo Technologies announced that Geograma, a geographic information systems, GIS, and location intelligence service provider, has awarded Otonomo a multi-year contract to provide multi-layered connected vehicle data designed to advance road safety in Spain. Geograma is integrating the granular connected vehicle data delivered through the Otonomo Smart Mobility Data Platform into its traffic platform and developing new road safety applications based on uniquely available extended vehicle sensor data. Geograma's GEOTRAFFIC platform provides connected vehicle data-based services to traffic management agencies, including traffic analytics and real-time traffic monitoring services which are deployed in regional Traffic Control Centers. "Having the right data is critical to effective traffic management. With access to traffic analysis and management capabilities, Geograma is able to provide a better understanding of traffic flow, which advances mobility and road safety," said Ben Volkow, CEO and co-founder of Otonomo. "We're thrilled that data from the Otonomo platform can support Geograma so effectively to create safer roads and deliver on the future of traffic management."

07:56 EDT VBL Therapeutics ceasing development of ofra-vec in all indications - Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics stated along with the company announcing financial results for the second quarter last night: "Following our announcement in July that the Phase 3 OVAL trial evaluating ofra-vec did not meet its primary endpoints, we began an internal strategic review of our development programs with the goal of maximizing shareholder value. We have taken steps to preserve capital, including the workforce reduction announced earlier in August and ceasing development of ofra-vec in all indications. We see opportunities to create value from our assets including from our Monocyte Targeting Technology, which offers a novel and differentiated approach to targeting inflammation and our gene therapy manufacturing facility. Our VB-601 program, the first candidate from the MTT program, remains on track and we plan to enter the clinic with this program in the fourth quarter of 2022." The company added: "Subsequent to the end of the second quarter, VBL announced that the OVAL phase 3 study did not meet either primary endpoint. VBL evaluated these subsequent events and determined that no adjustments to the June 30, 2022 financial statements were required as they were not known or expected as of that date. As the results are considered a triggering event, VBL will perform an impairment test on all of its long-lived assets in the third quarter of 2022 that may result in an impairment charge on such assets and potential new liabilities arising from the triggering event." In August, VBL retained Chardan to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. "Strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction or transactions involving VBL. VBL's board of directors has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic options at this time. There can be no assurance, however, that this process will result in any such transaction," the company added.

07:44 EDT Dorman Products introduces New Solutions Catalog - Dorman Products is announcing the launch of a new digital and print publication, the New Solutions Catalog, which is designed to help auto part counter representatives and repair shop service writers be more aware of Dorman's latest aftermarket-first products and growing category breadth.

07:37 EDT Trxade Health appoints Jeff Newell to advisory board - TRxADE HEALTH announced the appointment of Jeff Newell to the Company's advisory board. Mr. Newell is expected to serve as a strategic resource to TRxADE as it continues to develop trade relationships in the industry.

07:36 EDT FTI Consulting appoints Tracy Wilison as SMD, cybersecurity - FTI Consulting announced the appointment of Tracy Wilkison, who most recently was U.S. Attorney for the Central District of California, as a Senior Managing Director in the firm's Cybersecurity practice, further enhancing its presence on the West Coast. Her appointment will be effective September 12. Ms. Wilkison, who will be based in Los Angeles, spent more than 20 years with the U.S. Attorney's Office. She was appointed to serve as U.S. Attorney for the Central District of California in November 2021 after serving as Acting U.S. Attorney since January 2020.

07:34 EDT GMS Inc. names Leigh Dobbs Chief Human Resources Officer - GMS Inc. announced that Leigh Dobbs has been named Chief Human Resources Officer or CHRO, for GMS, effective September 6 . "I am pleased to welcome Leigh to our GMS team," said John C. Turner, Jr., President and CEO of GMS. "She brings extensive experience leading HR, which is crucial as we continue to execute against our strategic growth priorities, while also ensuring our commitment to the vision, mission and values of GMS. In her role as CHRO, Leigh will lead all aspects of our Human Resources efforts, including recruiting and retaining top talent, leadership development and training, compensation and benefits, HR operations, inclusion and diversity, and promoting our culture across the organization. I look forward to working with Leigh and the contributions she will make to the team."

07:32 EDT Lumos Pharma board authorizes $3M share repurchase program - Lumos Pharma announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of June 30, 2022, the Company had approximately $79.5 million of cash, cash equivalents, and marketable securities. The Company had approximately 8.4 million shares outstanding as of August 3, 2022.

07:32 EDT Polestar confirms plan to put Polestar electric roadster concept into production - Polestar confirmed plans to put the Polestar electric roadster concept into production. The production car is expected to launch in 2026 as the Polestar 6 electric performance roadster. Interested customers in all active Polestar markets are able to reserve a build slot online starting August 16.

07:23 EDT Walmart says actions to improve inventory put pressure on full-year outlook - "We're pleased to see more customers choosing Walmart during this inflationary period, and we're working hard to support them as they prioritize their spending. The actions we've taken to improve inventory levels in the U.S., along with a heavier mix of sales in grocery put pressure on profit margin for Q2 and our outlook for the year. We made good progress throughout the quarter operationally to improve costs in our supply chain, and that work is ongoing. We continue to build on our strategy to expand our digital businesses, including the continued strength we see in our international markets," Doug McMillon president and CEO, Walmart said.

07:17 EDT Walmart sees second half headwind of $2.1B - Sees FY23 adjusted operating income down 9%-11%.

07:15 EDT The Tile Shop announces $30M share repurchase authorization - Tile Shop announced that the Company's Board of Directors has authorized a share repurchase program pursuant to which the Company may purchase shares of its common stock for an aggregate repurchase price not to exceed $30M. After review and consideration of capital allocation alternatives with its financial advisor, the Independent Transaction Committee of the Board has unanimously recommended that the Board approve the $30M share repurchase program, and the members of the Board have unanimously approved this recommendation. Karla Lunan, Chief Financial Officer, stated, "We believe our shares are currently undervalued and based on the strength of our balance sheet, coupled with our long-term outlook, an opportunity exists to create value for our shareholders while continuing to invest in our key strategies."

07:13 EDT DoubleDown celebrates 12 years of DoubleDown Casino - DoubleDown Interactive celebrates 12 years since the launch of their flagship title. This milestone celebration started on August 14, 2022 with a countdown that gives away free prizes, leading up to the DoubleDown Birthday Bash on August 26 and 27, 2022. During the event, players are encouraged to complete slot quests and will earn a reward based on how many slot quests they complete.

07:11 EDT Societal CDMO signs over $9M sales, purchase agreement with David Weekley - Societal CDMO announced that it has signed a sales and purchase agreement to sell approximately 121 acres of lakefront land to David Weekley Homes for $9,075,000.00. The land is located adjacent to Societal's manufacturing facility in Gainesville, Georgia, and is being sought by David Weekley Homes, which operates in 19 cities across the U.S., for residential development. The closing of the sale is subject to completion of standard due diligence and other customary conditions. Subject to completion of diligence, Societal CDMO expects the sale to close in the second half of 2023 and intends to use the proceeds from the sale to strengthen its balance sheet by paying down a portion of its outstanding debt.

07:05 EDT WWE raises FY22 adjusted OIBDA view to $370M-$385M from $360M-$375M - The company said, "In February, the Company issued Adjusted OIBDA guidance of $360 - $375 million for the full year 2022. Based on outperformance through the first six months of the year as well as management's current expectations for the second half of the year, the Company is raising its guidance and now expects full year 2022 Adjusted OIBDA within a range of $370 - $385 million. This range of anticipated performance reflects the continued ramp-up of live events, including large-scale international events, and increased monetization of content, partially offset by increased production, content-related, and other expenses. "

07:04 EDT Genprex receives patent covering methods using REQORSATM Immunogene Therapy - Genprex announced that the U.S. Patent and Trademark Office, or USPTO, has granted Genprex U.S. Patent No: 11,278,592 B2. The patent covers methods of using REQORSATM Immunogene Therapy in conjunction with immune checkpoint inhibitors, through 2038. "This new patent provides critical protection for our REQORSA gene therapy in combination with a checkpoint inhibitor, for example an anti-PD1 antibody, to treat cancer. This is important as our ongoing Acclaim-2 Phase 1/2 clinical trial combines REQORSA with Keytruda, an anti-PD1 antibody, to treat non-small cell lung cancer," noted Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex. Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, REQORSA Immunogene Therapy, in combination with Keytruda in patients with late-stage non-small cell lung cancer whose disease progressed after treatment with Keytruda. More information on Acclaim-2 can be found at www.clinicaltrials.gov Identifier NCT05062980.

07:01 EDT Bristol-Myers and Turning Point announce expiration of waiting period for merger - Bristol Myers Squibb (BMY) and Turning Point Therapeutics (TPTX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of merger control clearance from the Federal Cartel Office of Germany, in connection with the previously announced offer to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1B. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, and the Offer was not extended. Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 41,896,678 shares of common stock were validly tendered, and not validly withdrawn pursuant to Offer, representing approximately 84% of the issued and outstanding shares of common stock. The parties expect the transaction to close on August 17 promptly following the acceptance of all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer.

06:49 EDT International Game subsidiary to debut Retailer Vue lottery terminal in Portugal - International Game announced that its subsidiary, IGT Global Solutions Corporation, has signed an agreement with Santa Casa da Misericordia de Lisboa, or SCML, to debut IGT's Retailer Vue lottery terminal in Portugal, following a competitive procurement. The delivery of up to 7,200 camera-based terminals is expected to be completed in 2023.

06:42 EDT AutoNation former director and investor Ed Lampert sells $22.8M in common stock - In a regulatory filing, AutoNation disclosed that its former director and investor Ed Lampert sold 183.5K shares of common stock on August 11th in a total transaction size of $22.8M.

06:39 EDT Zedge announces $1.5M share repurchase program - Zedge announced that its board of directors authorized a share repurchase program permitting the company to purchase up to an aggregate of 1.5M shares of Class B common stock.

06:35 EDT MediciNova to participate in RECLAIM clinical trial to evaluate MN-166 - MediciNova announced that it plans to participate in RECLAIM, or Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial, a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166, or ibudilast, and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19. MediciNova has reached an agreement to collaborate with the University Health Network, an academic health sciences center located in Toronto, which has the largest hospital-based research program in Canada. The lead principal investigator of this trial is Angela M. Cheung, Professor of Medicine, KY and Betty Ho Chair in Integrative Medicine, University of Toronto, Senior Scientist, Toronto General Hospital Research Institute, Schroeder Arthritis Institute, and a physician at the University Health Network and Sinai Health System. The trial is funded by the Canadian government through the Canadian Institutes of Health Research. The initiation of this trial is pending protocol finalization and regulatory review.

06:32 EDT Immunic receives notice of allowance from USPTO for IMU-856 patent - Immunic announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office, or USPTO, for patent application 16/646130, entitled, "Compound Having Cyclic Structure." The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential patent term extension (PTE). The patent application was originally filed by Daiichi Sankyo, which discovered IMU-856. In 2018, Immunic and Daiichi Sankyo entered into a global option and license agreement, granting Immunic the exclusive right to license IMU-856, which was subsequently exercised by Immunic in 2020. The license included exclusivity on the composition-of-matter patent.

06:18 EDT Amphastar announces FDA approval for Epinephrine injection NDA - Amphastar announced that the FDA has approved the company's new drug application, or NDA, for Epinephrine injection USP, 1 mg/10mL Single Dose Pre-Filled Syringe. Epinephrine injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. For the past 30 years, the company has sold and marketed Epinephrine injection under the "grandfather" exception to the FDA's "Prescription Drug Wrap-Up" program. Net revenues for the company's Epinephrine injection for the year ended December 31, 2021, were $27.8M. Epinephrine injection is the final product that we market under the grandfather exception.

06:02 EDT Babylon Holdings responds to M&A speculation - Babylon Holdings released a statement yesterday addressing the M&A speculation and a more than 20% increase in the company's stock price at one point during the trading day that led to the New York Stock Exchange's trading halt of the company's ordinary shares. "In the second quarter of 2022, Babylon delivered very strong financial results and operational performance that demonstrate its continued momentum. Babylon is taking active steps to maximize shareholder value and to improve its shareholder base and capital structure, as discussed by Ali Parsa, CEO and Founder of Babylon, in the company's second quarter earnings call. Babylon will continue to take further steps and consider opportunities to maximize value for shareholders. The company's focus will remain on delivering on its promise, maintaining its quality and moving closer to profitability. Babylon believes the stock price will reflect these efforts over time."

05:43 EDT Uber to boost prices by about 5% in London to attract more drivers - Uber announced that it is planning to attract 8,000 more drivers in London in order to meet the growing demand in the capital. "The introduction of protections such as holiday pay and access to a pension plan has already led to more than 10,000 new drivers signing up with Uber in recent months, but Uber is taking steps to further grow its driver base in London and across the UK in order to meet the growing demand and boost service levels. In order to do this, Uber will further increase driver rates across London and the UK. The per mile rate and minimum fare for drivers, which, for example, will, on average, lead to a 5% increase in fares in London. Price changes will vary city by city and Uber is also making changes to peak hours and minimum fares to help boost driver earning opportunities, while keeping prices competitive and reliable for riders." Reference Link

05:21 EDT Philips announces Roy Jakobs to succeed Frans van Houten as CEO - Philips announced that Roy Jakobs is proposed to succeed Frans van Houten as president and CEO, effective October 15. The supervisory board and current Philips CEO Frans van Houten have agreed that with the end of his third term in sight, the time is right for the change in leadership. After an evaluation of external and internal candidates, the supervisory board has unanimously decided to propose Roy Jakobs as the next president and CEO of Royal Philips to its general meeting of shareholders. Jakobs brings a strong international, operational and transformational track record, as well as a deep understanding of Philips, which is critical at this important juncture in the company's growth journey. Jakobs has strengthened the company's Connected Care portfolio through acquisitions across hospital and ambulatory care settings. An extraordinary general meeting, or EGM, of shareholders will be held on September 30 to appoint Jakobs as president and CEO, effective October 15. Frans van Houten will act as advisor to the company - supporting the transition - until April 30, 2023.

05:15 EDT Mainz Biomed, Dante Genomics start ColoAlert commercial program in Italy and UAE - Mainz Biomed and Dante Genomics announced the formal commencement of ColoAlert's consumer commercial program in Italy and the United Arab Emirates, or UAE. ColoAlert is an at-home detection test for colorectal cancer, or CRC, currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante's database and sold via Dante's, region-specific, e-commerce websites.